- Home
- BNTC vs PROK Comparison
BNTC vs PROK Comparison
Compare BNTC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTC | PROK |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | 231 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.4M | 359.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BNTC | PROK |
|---|---|---|
| Price | $11.40 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $27.67 | $7.40 |
| AVG Volume (30 Days) | 79.6K | ★ 720.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $9.85 | $0.54 |
| 52 Week High | $17.15 | $7.13 |
Technical Indicators
Market Signals| Indicator | BNTC | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 45.39 |
| Support Level | $9.91 | $1.73 |
| Resistance Level | $13.40 | $2.58 |
| Average True Range (ATR) | 0.68 | 0.12 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 38.12 | 46.74 |
Price Performance
Historical ComparisonAbout BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.